Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission

Impaired cardiac microvascular function contributes to diabetic cardiovascular complications although effective therapy remains elusive. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor recently approved for treatment of type 2 diabetes, promotes glycosuria excretion and offers card...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Redox Biol
Glavni autori: Zhou, Hao, Wang, Shuyi, Zhu, Pingjun, Hu, Shunying, Chen, Yundai, Ren, Jun
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5756062/
https://ncbi.nlm.nih.gov/pubmed/29306791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.redox.2017.12.019
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items